TRIM71 and cyclic hematopoiesis: These data suggest that gain-of-function mutations in the RNA-binding domain of Trim71 cause CH via distinct pathological mechanisms, that CH patients could be stratified based on these distinct mechanisms, and that precise therapeutic strategies could be designed for genetically diverse etiologies of CH.